{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:42:12Z","timestamp":1760532132131,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T00:00:00Z","timestamp":1691884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejps.2023.106565","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T20:59:17Z","timestamp":1692046757000},"page":"106565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies"],"prefix":"10.1016","volume":"190","author":[{"given":"Yun","family":"Kuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5930-586X","authenticated-orcid":false,"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2023.106565_bib0025","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Aa","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106565_bib0013","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s12035-015-9136-z","article-title":"GM1 ganglioside: past studies and future potential","volume":"53","author":"Aureli","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejps.2023.106565_bib0002","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/sj.leu.2402040","article-title":"Incidence of hematological malignancies in Martinique, French West Indies, overrepresentation of multiple myeloma and adult T cell leukemia\/lymphoma","volume":"15","author":"Besson","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2023.106565_bib0009","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejps.2023.106565_bib0004","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11899-017-0368-z","article-title":"Current review on high-risk multiple myeloma","volume":"12","author":"Chan","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.ejps.2023.106565_bib0012","first-page":"23","article-title":"Effects of ganglioside GM1 on reduction of brain edema and amelioration of cerebral metabolism after traumatic brain injury","volume":"6","author":"Chen","year":"2003","journal-title":"Chin. J. Traumatol."},{"key":"10.1016\/j.ejps.2023.106565_bib0019","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.biopha.2012.01.002","article-title":"The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study","volume":"66","author":"Chen","year":"2012","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2023.106565_bib0023","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.2042-7158.1990.tb06564.x","article-title":"Pharmacokinetics of GM1 ganglioside following parenteral administration","volume":"42","author":"Cornelli","year":"1990","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106565_bib0015","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1074\/jbc.270.7.3074","article-title":"Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors","volume":"270","author":"Ferrari","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2023.106565_bib0007","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/bja\/aex229","article-title":"Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review","volume":"119","author":"Flatters","year":"2017","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejps.2023.106565_bib0014","doi-asserted-by":"crossref","first-page":"9558","DOI":"10.3390\/ijms24119558","article-title":"Ganglioside GM1 and the central nervous system","volume":"24","author":"Guo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2023.106565_bib0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejps.2023.106565_bib0010","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1159\/000365534","article-title":"Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy","volume":"37","author":"Koeppen","year":"2014","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.ejps.2023.106565_bib0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ejps.2023.106565_bib0027","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2215\/CJN.00340118","article-title":"Clinical pharmacokinetics in kidney disease: fundamental principles","volume":"13","author":"Lea-Henry","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol.: CJASN"},{"key":"10.1016\/j.ejps.2023.106565_bib0001","first-page":"373","article-title":"Multiple myeloma: diagnosis and treatment","volume":"95","author":"Michels","year":"2017","journal-title":"Am. Fam. Phys."},{"key":"10.1016\/j.ejps.2023.106565_bib0008","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejps.2023.106565_bib0017","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/jnc.12760","article-title":"GM1 ganglioside enhances Ret signaling in striatum","volume":"130","author":"Newburn","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejps.2023.106565_bib0016","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbalip.2014.12.004","article-title":"GM1 and GD1a gangliosides modulate toxic and inflammatory effects of E. coli lipopolysaccharide by preventing TLR4 translocation into lipid rafts","volume":"1851","author":"Nikolaeva","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2023.106565_bib0022","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/clpt.1991.118","article-title":"Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers","volume":"50","author":"Rost","year":"1991","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106565_bib0011","doi-asserted-by":"crossref","first-page":"41269","DOI":"10.1038\/srep41269","article-title":"Restoring GM1 ganglioside expression ameliorates axonal outgrowth inhibition and cognitive impairments induced by blast traumatic brain injury","volume":"7","author":"Rubovitch","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2023.106565_bib0018","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.molcel.2009.10.021","article-title":"GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis","volume":"36","author":"Sano","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejps.2023.106565_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.637593","article-title":"Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross-sectional study","volume":"12","author":"Selvy","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106565_bib0021","first-page":"55","article-title":"The effects of ganglioside-monosialic acid in taxane-induced peripheral neurotoxicity in patients with breast cancer: a randomized trial","volume":"112","author":"Su","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejps.2023.106565_bib0026","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2165\/00003088-198005060-00002","article-title":"Hepatic disease and drug pharmacokinetics","volume":"5","author":"Williams","year":"1980","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106565_bib0024","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0031-6989(85)90032-3","article-title":"Radioiodinated ganglioside GM1: a potential tool for the investigation of ganglioside function in vivo","volume":"17","author":"Zalutsky","year":"1985","journal-title":"Pharmacol. Res. Commun."},{"key":"10.1016\/j.ejps.2023.106565_bib0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1477-7819-11-19","article-title":"Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors","volume":"11","author":"Zhu","year":"2013","journal-title":"World J. Surg. Oncol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723001951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723001951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:08:36Z","timestamp":1760530116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098723001951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":27,"alternative-id":["S0928098723001951"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106565","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106565"}}